ASIA GOUT DISEASE TREATMENT MARKET ANALYSIS(2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
ASIA GOUT DISEASE TREATMENT MARKET
ANALYSIS(2020-2027)

• Asia Gout Disease Treatment Market, By Drug Class
  (Nonsteroidal Anti-inflammatory Drugs (NSAIDs),
  Corticosteroids, Colchicine, and Urate-lowering
  Agents), By Route of Administration (Oral and
  Injectable), By Distribution Channel (Hospital
  Pharmacies, Retail Pharmacies, and Online
  Pharmacies), and By Country (China, India, Japan,
  South Korea, Thailand, Indonesia, Singapore,
  Vietnam, and Rest of Asian Countries) - Size,
  Share, Outlook, and Opportunity Analysis, 2020 -
  2027

3

• Gout is a condition that is characterized by the
  formation of excess uric acid in body tissues
  that result in the formation of crystals of
  monosodium urate. Symptoms of gout include
  intense pain, swelling, and stiffness in the
  joints. Asia gout disease treatment market is
  expected to witness significant growth due to
  increasing number of pipeline products. For
  instance, Shanton Pharma Co., Ltd, a China-based
  biotech company, has its major drug candidate
  SAP-001 in pipeline. SAP-001 is developed as a
  new investigational Uric Acid Transporter 1
  (URAT1) inhibitor for the chronic management of
  hyperuricemia and gout.

4

• Asia Gout Disease Treatment Market Impact of
  Coronavirus (Covid-19) Pandemic
• The Covid 19 pandemic is expected to drive
  growth of the Asia gout disease treatment market
  over the forecast period. Since December 2019, a
  novel coronavirus spread throughout China and
  across the world, causing a continuous increase
  in confirmed cases within a short period of time.
  The disease has spread to more than 100 countries
  across the globe and the World Health
  Organization declared it as a public health
  emergency. For instance, according to the World
  Health Organization Coronavirus Disease
  (COVID-19) Dashboard (WHO) report, the
  manifestation of the coronavirus disease
  (COVID-19) has resulted in more than 11 million
  infected individuals worldwide as of July 2020.

5

• Furthermore, according to the CreakyJoints, May
  2020, people with gout may be considered in a
  higher-risk group for potential COVID-19
  complications. The coronavirus (COVID 19)
  pandemic and lockdowns in various countries
  across the globe have impacted the financial
  status of businesses across all sectors. The
  private healthcare sector is one the sectors,
  which has been majorly impacted by the COVID 19
  pandemic.
• The Asia gout disease treatment market is
  estimated to be valued at US 643.55 Million in
  2020 and is expected to exhibit a CAGR of
  9.1 during the forecast period (2020-2027).

6

• Figure 1 Asia Gout Disease Treatment
  Market Share () Analysis, By Drug Class, 2020

7

• Asia gout disease treatment market is expected to
  grow significantly in the near future, owing to
  presence of major market players
• Market players are more focused on adoption of
  inorganic growth strategies such as acquisitions,
  collaborations, and partnerships to strengthen
  their anti-gout drugs portfolio. For instance, in
  September 2019, Simcere Pharmaceutical Group and
  JW Pharmaceutical (both China-based companies)
  entered into a collaboration and exclusive
  license agreement for the development of
  anti-gout drug candidate URC-102 in China. Under
  this agreement, the responsibilities of clinical
  trial and registration will be taken by Simcere
  Pharmaceutical Group. The candidate, URC-102, is
  a selective inhibitor of uric acid transporter
  (URAT-1) and it is in Phase IIb clinical trial in
  patients with gout disease in South Korea.

8

• Furthermore, big pharmaceutical companies such as
  Takeda Pharmaceutical and AstraZeneca adopted
  inorganic growth strategies. For instance, in
  April 2012, Takeda Pharmaceutical (Japan-based)
  acquired the URL Pharma Inc., a
  Philadelphia-based company, in order to expand
  its gout disease treatment portfolio with the
  acquisition of marketed gout therapy Colcrys
  (colchicine), developed by URL Pharma Inc.
• Similarly, in December 2018, InventisBio
  announced that it had signed a collaboration
  agreement with Betta Pharma. Under this
  agreement, InventisBio will out-license D-0316's
  rights in China (including mainland China, Hong
  Kong, and Taiwan) to Betta Pharma and to
  co-develop this drug in China. Betta Pharma will
  have the exclusive commercialization rights of
  D-0316 product in China.

9
(No Transcript)
10

• Asia Gout Disease Treatment Market Restraints
• The adverse effects and risks associated with
  drugs such as NSAIDS and urate-lowering agents is
  major factor restraining growth of this market.
  Most of the gout drugs are associated with some
  severe side effects, which may lead to decrease
  in demand for these drugs. Nonsteroidal
  anti-inflammatory drugs (NSAIDs) may cause some
  gastric problems such as indigestion. In some
  cases, these drugs can cause gastric ulcers,
  bleeding, and rashes in gastrointestinal GI
  tract. Moreover, side effects such as
  intolerability and contraindication may limit the
  use of these drugs in the treatment of gout.
• For instance, in February 2019, the U.S. Food and
  Drug Administration (FDA) announced to add a new
  boxed warning for febuxostat, as there is
  increased risk of death associated with Uloric
  (febuxostat) compared to another gout medicine,
  allopurinol. Febuxostat belongs to the
  urate-lowering agents.

11

• Figure 2 Asia Gout Disease Treatment
  Market Value (US Mn) Y-o-Y Growth (),
  2017-2027

12

• Asia Gout Disease Treatment Market Competitive
  Landscape
• Some of the key players operating in the Asia
  gout disease treatment market include AstraZeneca
  Plc, Takeda Pharmaceutical Company Limited,
  Teijin Pharma Limited, Hikma Pharmaceuticals
  Plc., Hikma Pharmaceuticals Plc., Zyla Life
  Sciences, Horizon Therapeutics plc, JW
  Pharmaceutical CORPORATION, and LG Chem.

13

• Figure 3 Value Chain Analysis

14

• GCC Medical Gloves Market Competitive Landscape
• Major players operating in GCC medical gloves
  market include, Paul Hartmann AG, Hotpack
  Packaging Industries, LLC, Falcon (Falcon Pack),
  Top Glove Corp Bhd., Deeko Bahrain, Salalah
  Medical Supplies Mfg. Co. LLC, United Medical
  Industries Co. Ltd., and NAFA (NAFA Enterprises,
  Ltd.).

15

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  market-insight/asia-gout-disease-treatment-market-
  4141

16
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

17
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

18

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/